Heterocyclic HIV-protease inhibitors

Current Medicinal Chemistry

Volumn 20, Issue 30, 2013, Pages 3693-3710

  Calugi, C ^a   Guarna, A ^a   Trabocchi, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Amino acid; Enzyme inhibition; Infectious disease; Peptidomimetic; Small molecule

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; AMPRENAVIR; ASPARTIC PROTEINASE INHIBITOR; ATAZANAVIR; DARUNAVIR; HETEROCYCLIC COMPOUND; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; MOZENAVIR; NELFINAVIR; PEPSTATIN; PYRROLIDINE DERIVATIVE; RITONAVIR; SAQUINAVIR; SULFONAMIDE; TIPRANAVIR; TRIAZOLE DERIVATIVE; UREA DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG STRUCTURE; ENTROPY; ENZYME BINDING; ENZYME INHIBITOR INTERACTION; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; IN VITRO STUDY; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY;

DRUG DESIGN; HETEROCYCLIC COMPOUNDS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR;

EID: 84883334389     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990135     Document Type: Article

References (97)

1. Rawlings, N. D.; Morton, F. R.; Kok, C. Y.; Kong, J.; Barret, A. J. MEROPS: the peptidase database. Nucleic Acids Res., 2008, 36, D320-325.
2. Barrett, A. J. Rawlings, N. D.; Woessner, J. F. Jr (eds) Handbook of proteolytic enzymes 2nd edn (Academic, Amsterdam, 2004).
3. Turk, B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug. Discov., 2006, 5, 785-799.
4. Bernstein, P. R.; Edwards, P. D.; Williams, J. C. Inhibitors of human leukocyte elastase. Prog. Med. Chem., 1994, 31, 59-120.
5. Fath, M. A.; Wu, X.; Hileman, R. E.; Linhardt, R. J.; Kashem, M. A.; Nelson, R. M.; Wright, C. D.; Abraham, W. M. Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma. J. Biol. Chem., 1998, 273, 13563-13569.
6. Tanaka, R. D.; Clark, J. M.; Warne, R. L.; Abraham, W. M.; Moore, W. R. Mast cell tryptase: a new target for therapeutic intervention in asthma. Int. Arch. Allergy Immunol., 1995, 107, 408-409.
7. Yan, R.; Bienkowski, M. J.; Shuck, M. E.; Miao, H.; Tory, M. C.; Pauley, A. M.; Brashier, J. R.; Stratman, N. C.; Mathews, W. R.; Buhl, A. E.; Carter, D. B.; Tomasselli, A. G.; Parodi, L. A.; Heinrikson, R. L.; Gurney, M. E. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature, 1999, 402, 533-537.
8. Beckett, R. P.; Davidson, A. H.; Drummond, A. H.; Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research. Drug Discov. Today, 1996, 1, 16-26.
9. Johnson, L. L.; Dyer, R.; Hupe, D. J. Matrix metalloproteinases. Curr. Opin. Chem. Biol., 1998, 2, 466-471.
10. Yan, S.; Sameni, M.; Sloane, B. F. Cathepsin B and human tumor progression. Biol. Chem., 1998, 379, 113-123
11. Tomasselli, A. G.; Heinrikson, R. L. Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim. Biophys. Acta, 2000, 1477, 189-214.
12. Darke, P. L.; Huff, J. R. HIV protease as an inhibitor target for the treatment of AIDS. Adv. Pharmacol., 1994, 25, 399-454.
13. Naglik, J. R.; Challacombe, S. J.; Hube, B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol. Mol. Biol. Rev., 2003, 67, 400-428.
14. Ersmark, K.; Samuelsson, B.; Hallberg, A. Plasmepsins as potential targets for new antimalarial therapy. Med. Res. Rev., 2006, 26, 626-666.
15. Dash, C.; Kulkarni, A.; Dunn, B.; Rao, M. Aspartic peptidase inhibitors: implications in drug development. Crit. Rev. Biochem. Mol. Biol., 2003, 38, 89-119.
16. Dun, B. M. Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem. Rev., 2002, 102, 4431-4458.
17. Wlodawer, A.; Gustchina, A. Structural and biochemical studies of retroviral proteases. Biochim. Biophys. Acta, 2000, 1477, 16-34.
18. Cutfield, S. M.; Dodson, E. J.; Anderson, B. F.; Moody, P. C.; Marshall, C. J.; Sullivan, P. A.; Cutfield, J. F. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure, 1995, 3, 1261-1271.
19. Kohl, N.E.; Emini, E.A.; Schleif, W. A.; Davis, L.J.; Heimbach, J.C.; Dixon, R.A.; Scolnick, E.M., Sigal, I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U. S. A., 1988, 85, 4686-4690.
20. Navia, M.A.; Fitzgerald, P.M.; Mckeever, B.M.; Leu, C.T.; Heimbach, J. C.; Herber, W.K.; Sigal, I.S.; Darke, P.L.; Springer, J.P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature, 1989, 337, 615-620.
21. Rich, D.H.; Bursavich, M. G.; Estiarte, M. A. Discovery of nonpeptide, peptidomimetic peptidase inhibitors that target alternate enzyme active site conformations. Biopolymers, 2002, 66, 115-125.
22. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: current status and future prospects. J. Med. Chem. 2000, 43, 305-341.
23. Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun., 1967, 27, 157-162.
24. Craig, J. C.; Duncan, I. B.; Hockley, D.; Grief, C.; Roberts, N. A.; Mills, J. S. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res., 1991, 16, 295-305.
25. Kempf, D. J.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentge, C. A.; Green, B. E.; Fino, L.; Park, C. H.; Kong, X. P. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 2484-2488.
26. Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J. F.; Boross, P.; Wang, Y. F.; Tie, Y.; Volarath, P.; Gaddis, L.; Harrison, R. W.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother., 2003, 47, 3123-3129.
27. Partaledis, J. A.; Yamaguchi, K.; Tisdale, M.; Blair, E. E.; Falcione, C.; Maschera, B.; Myers, R.E.; Pazhanisamy, S.; Futer, O.; Cullinan, A. B. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol., 1995, 69, 5228-5235.
28. Patick, A. K.; Mo, H.; Markowitz, M.; Appelt, K.; Wu, B.; Musick, L.; Kalish, V.; Kaldor, S.; Reich, S.; Ho, D.; Webber, S.; Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother., 1996, 40, 292-297.
29. Robinson B. S.; Riccardi, K. A.; Gong, Y. F.; Guo, Q.; Stock, D. A.; Blair, W. S.; Terry, B. J.; Deminie, C. A.; Djang, F.; Colonno, R. J.; Lin, P. F. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemoter., 2000, 44, 2093-2099.
30. Sham, H. L.; Kempf, D. J.; Molla, A.; Marsh, K. C.; Kumar, G. N.; Chen, C. M.; Kati, W.; Stewart, K.; Lal, R.; Hsu, A.; Betebenner, D.; Korneyeva, M.; Vasavanonda, S.; McDonald, E.; Saldivar, A.; Wideburg, N.; Chen, X.; Niu, P.; Park, C.; Jayanti, V.; Grabowski, B.; Granneman, G. R.; Sun, E.; Japour, A. J.; Leonard, J. M.; Plattner, J. J.; Norbeck, D. W. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother., 1998, 42, 3218-3224.
31. Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. U. S. A., 1994, 91, 4096-4100.
32. Erickson J. W. HIV protease as a target for AIDS therapy. In: Ogden, R. C.; Flexner, C.W. editors. Protease inhibitors in AIDS therapy. New York: Marcel Dekker, 2001, 1-25.
33. Mastrolorenzo, A.; Rusconi, S.; Scozzafava, A.; Barbaro, G.; Supuran, C. T. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr. Med. Chem., 2007, 14, 2734-2748.
34. Supuran, C. T.; Casini, A.; Scozzafava, A. Protease inhibitors of the sulfonamide type: anticancer, anti-inflammatory, and antiviral agents. Medicinal Research Reviews, 2003, 23, 535-558.
35. Ghosh, A. K.; Anderson, D. D. Tetrahydrofuran, tetrahydropyran, triazoles, and related heterocyclic derivatives as HIV protease inhibitors. Future Med. Chem., 2011, 3, 1181-1197.
36. Qiu, X.; Liu Z. P. Recent developments of peptidomimetic HIV-1 protease inhibitors. Curr. Med. Chem., 2011, 18, 4513-4537.
37. Ghosh, A. K.; Sridhar, P. R.; Leshchenko, S.; et al. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J. Med. Chem., 2006, 49, 5252-5261.
38. Ghosh, A. K.; Martyr, C. D.; Mitsuya, H.; et al. Design of substituted bis-tetrahydrofuran (bis-THF)-derived potent HIV-1 protease inhibitors, protein-ligand X-ray structure, and convenient synthesis of bis-THF and substituted bis-THF ligands. Med. Chem. Lett., 2011, 2, 298-302.
39. Ghosh, A. K.; Xu, C. X.; Rao, K. V.; Baldridge, A.; Agniswamy, J.; Wang, Y. F.; Wber, I. T.; Aoki, M.; Miguel, S. G.; Amano, M.; Mitsuya, H. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors. ChemMedChem, 2010, 5, 1850-1854.
40. Ghosh, A. K.; Chapsal, B. D.; Baldridge, A.; Ide, K.; Koh, Y.; Mitsuya, H. Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors. Org. Lett., 2008, 10, 5135-5138.
41. Ghosh, A. K.; Gemma, S.; Takayama, J.; Baldridge, A.; Leshchenko-Yashchuk, S.; Miller, H. B.; Wang, Y. F.; Kovalevsky, A. Y.; Koh, Y.; Weber, I. T.; Mitsuya, H. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and proteinligand x-ray studies. Org. Biomol. Chem., 2008, 6, 3703-3713.
42. Ghosh, A.; Gemma, S.; Baldridge, A.; et al. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation and protein-ligand x-ray studies. J. Med. Chem., 2008, 51, 6021-6033.
43. Hohlfeld, K.; Tomassi, C.; Wegner, J. K.; Kesteleyn, B.; Linclau, B. Disubstituted Bis-THF moieties as new P2 ligands in nonpeptidal HIV-1 protease inhibitors. Med. Chem. Lett., 2011, 2, 461-465.
44. Kim, R. M.; Rouse, E. A.; Chapman, K. T.; Schleif, W. A.; Olsen, D. B.; Stahlhut, M.; Rutkowski, C. A.; Emini, E. A.; Tata, J. R. P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1. Bioorg. Med. Chem. Lett., 2004, 14, 4651-4654.
45. Mimoto, T.; Terashima, K.; Nojima, S.; Takaku, H.; Nakayama, M.; Shintani, M.; Yamaoka, T.; Hayashi, H. Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure. Bioorg. Med. Chem., 2004, 12, 281-293.
46. Koh, Y.; Das, D.; Leschenko, S.; Nakata, H.; Ogata-Aoki, H.; Amano, M.; Nakayama, M.; Ghosh, A. K.; Mitsuya, H.; GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother., 2009, 53, 997-1006.
47. Ghosh, A. K.; Leshchenko-Yashchuk, S.; Anderson, D. D.; Hong, L.;Baldridge, A.; Noetzel, M.; Miller, H. B.; Tie, Y.; Wang, Y. F.; Koh, Y.; Weber, I. T.; Mitsuya, H. Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation and protein-ligand x-ray studies. J. Med. Chem., 2009, 52, 3902-3914.
48. Ghosh, A., K.; Kulkarni, S.; Anderson, D. D.; Hong, L.; Baldridge, A.; Wang, Y. F.; Chumanevich, A. A.; Kovalevsky, A. Y.; Tojo, Y.; Amano, M.; Koh, Y.; Tang, J.; Weber, I. T.; Mitsuya, H. Design, synthesis, protein-ligand x-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance. J. Med. Chem., 2009, 52, 7689-7705.
49. Sommadossi, J. P. HIV protease inhibitors: pharmacologic and metabolic distinctions. AIDS, 1999, 13, S29-S40.
50. Mallewa, J. E.; Wilkins, E.; Vilar, J.; Mallewa, M.; Doran, D.; Back, D.; Pirmohamed, M. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutics options. J. Antimicrob. Chemotherap., 2008, 62, 648-660.
51. Carr, A.; Toxicity of antiretroviral therapy and implications for drug development. Nature, Rev. Drug Des., 2003, 2, 624-634.
52. Wensing, A. M. J.; Van Maarseveen, N. M.; Nijhuis, M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antivir. Res., 2010, 85, 59-74.
53. Ghosh, A. K.; Anderson, D. D.; Weber, I., T.; Mitsuya, H. Enhancing protein backbone binding- a fruitful concept for combating drug-resistant HIV. Angew. Chem. Int. Ed., 2012, 51, 1778-1802.
54. Turner, S. R.; Strohbach, J. W.; Tommasi, R. A.; Aristoff, P. A.; Johnson, P. D.; Skulnick, H. I.; Dolak, L. A.; Seest, E. P.; Tomich, P. K.; Bohanon, M. J.; Horng, M. M.; Lynn, J. C.; Chong, K. T.; Hinshaw, R. R.; Watenpaugh, K. D.; Janakiraman, M. N.; Thaisrivongs, S. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem., 1998, 41, 3467-3476.
55. Larder, B. A.; Hertogs, K.; Bloor, S.; Van den Eynden, C.; DeCian, W.; Wang, Y.; Freimuth, W. W.; Tarpley, G. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS, 2000, 14, 1943-1948.
56. Rusconi, S.; La Seta Catamancio, S.; Citterio, P.; Kurtagic, S.; Violin, M.; Balotta, C.; Moroni, M.; Galli, M.; D'arminio-Monforte, A. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitor. Antimicrob. Agents Chemother., 2000, 44, 1328-1332.
57. Lam, P. Y.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; et al. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science, 1994, 263, 380-384.
58. Winslow, D. L.; Reid, C. D.; Garber, S.; Aldrich, P.; Scarnati, H.; Anton, E.; Otto, M. J.; DMP450, a new cyclic urea inhibitor of HIV protease with potent in vitro antiviral activity. Antiviral Res., 1995, 26, 237.
59. Otto, M. J. et. al. In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrob. Agents Chemother., 1993, 37, 2606-2611.
60. Rayner, M. M. et al. DMP323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein. Antimicrob. Agents Chemother., 1994, 38, 1635-1640.
61. Hodge, C. N.; Aldrich, P. E.; Bacheler, L. T.; Chang, C. H.; Eyermann, C. J.; Garber, S.; Grubb, M.; Jackson, D. A.; Jadhav, P. K.; Korant, B.; Lam, P. Y. S.; Maurin, M. B.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Reid, C.; Sharpe, T. R.; Shum, L.; Winslow, D. L.; Erickson-Viitanen, S.; Improved cyclic urea inhibitor of the HIV protease: synthesis, potency, resistance profile, human pharmacokinetics and x-ray crystal structure of DMP450. Chem. Biol., 1996, 3, 301-314.
62. Han, Q.; Chang, C. H.; Li, R.; Ru, Y.; Jadhav, P. K.; Lam, P. Y. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency. J. Med. Chem., 1998, 41, 2019-2028.
63. Rodgers, J. D.; Lam, P. Y.; Johnson, B. L.; Wang, H.; Li, R.; Ru, Y.; Ko, S. S.; Seitz, S. P.; Trainor, G. L.; Andreson, P. S.; Klabe, R. M.; Bacheler, L. T.; Cordova, B.; Garber, S.; Reid, C.; Wright, M. R.; Chang, C. H.; Erickson-Viitanen, S. Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. Chem. Biol., 1998, 5, 597-608.
64. Kaltenbach, III, R. F.; Patel, M.; Waltermire, R. E.; Harris, G. D.; Stone, B. R.; Klabe, R. M.; Garber, S.; Bacheler, L. T.; Cordova, B. C.; Logue, K.; Wright, M. R.; Erickson-Viitanen, S.; Trainor, G. L. Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors. Bioorg. Med. Chem. Lett., 2003, 13, 605-608.
65. Garg, R.; Bhhatarai, B. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR. Bioorg. Med. Chem., 2004, 12, 5819-5831.
66. Vijjulatha, M.; Kanth, S. S. Computational design of novel cyclic urea as HIV-1 protease inhibitor. Central Eur. J. Chem., 2007, 5, 1064-1072.
67. Takkis, K.; Sild, S. QSAR modeling of HIV-1 protease inhibition on six and seven-membered cyclic ureas. QSAR Comb. Sci., 2009, 1, 52-58.
68. Sham, H. L.; Zhao, C.; Marsh, K. C.; Betebenner, D. A.; Lin, S.; Rosenbrook, W. Jr.; Herrin, T.; Li, L.; Madigan, D.; Vasavanonda, S.; Molla, A.; Saldivar, A.; Mcdonald, E.; Wideburg, N. E.; Kempf, D. J.; Norbeck, D. W.; Plattner, J. J. Novel azacyclic ureas that are potent inhibitors of the HIV-1 protease. Biochem. Biophys. Res. Commun., 1996, 225, 436-440.
69. Sham, H. L.; Zhao, C.; Stewart, K. D.; Betebenner, D. A.; Lin, S.; Park, C. H.; Kong, X.; Rosenbrook, W.; Herrin, T.; Madigan, D.; Vasavanonda, S.; Lyons, N.; Molla, A.; Saldivar, A.; Marsh, K. C.; Mcdonald, E.; Wideburg, N. E.; Denissen, J. F.; Robins, T.; Kempf, D. J.; Plattner, J. J.; Norbeck, D. W. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease. J. Med. Chem., 1996, 39, 392-397.
70. Zhao, C.; Sham, H. L.; Minghua, S.; Stoll, V. S.; Stewart, K. D.; Lin, S.; Mo, H.; Vasavanonda, S.; Saldivar, A.; Park, C.; Mcdonald, E. J.; Marsh, K. C.; Klein, L. L.; Kempf, D. J.; Norbeck, D. W. Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains. Bioorg. Med. Chem. Lett., 2005, 15, 5499-5503.
71. Hultén, J.; Bonham, N. M.; Nillroth, U.; Hansson, T.; Zuccarello, G.; Bouzide, A.; Åqvist, J.; Classon, B.; Danielson, U. H.; Karlén, A.; Kvarnström, I.; Samuelsson, B.; Hallberg, A. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies and computational predictions of binding affinities. J. Med. Chem., 1997, 40, 885-897.
72. Bäckbro, K.; Löwgren, S.; Österlund, K.; Atepo, J.; Unge, T. Unexpected binding mode of a cyclic sulfonamide HIV-1 protease inhibitor. J. Med. Chem., 1997, 40, 898-902.
73. Hultén, J.; Andersson, H. O.; Schaal, W.; Danielson, H. U.; Classon, B.; Kvarnström, I.; Karlén, A.; Unge, T.; Samuelsson, B.; Hallberg, A. Inhibitors of the C2-symmetric HIV-1 protease: nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2' side chains. J. Med. Chem., 1999, 42, 4054-4061.
74. Schaal, W.; Karlsson, A.; Ahlsén, G.; Lindberg, J.; Andersson, H. O.; Danielson, H. U.; Classon, B.; Unge, T.; Samuelsson, B.; Hultén, J.; Hallberg, A.; Karlén, A. Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors. J. Med. Chem., 2001, 44, 155-169.
75. Ax, A.; Schaal, W.; Vrang, L.; Samuelsson, B.; Hallberg, A.; Karlén, A., Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'. Bioorg. Med. Chem., 2005, 13, 755-764.
76. Gold, H.; Ax, A.; Vrang, L.; Samuelsson, B.; Karlén, A.; Hallberg, A.; Larhed, M. Fast and selective synthesis of novel cyclic sulfamide HIV-1 protease inhibitors under controlled microwave heating. Tetrahedron, 2006, 62, 4671-4675.
77. Ax, A.; Joshi, A. A.; Orrling, K. M.; Vrang, L.; Samuelsson, B.; Hallberg, A.; Karlén, A.; Larhed, M. Synthesis of a small library of non-symmetric cyclic sulfamide HIV-1 protease inhibitors. Tetrahedron, 2010, 66, 4049-4056.
78. Vara Prasad, J. V. N.; Para, K. S.; Lunney, E. A.; Ortwine, D. F.; Dunbar Jr., J. B.; Ferguson, D.; Tummino, P. J.; Hupe, D.; Tait, B. D.; Domagala, J. M.; Humblet, C.; Bhat, T. N.; Liu, B.; Guerin, D. M. A.; Baldwin, E. T.; Erickson, J. W.; Sawyer, T. K. Novel series of achiral, low molecular weight, and potent HIV-1 protease inhibitors. J. Am. Chem. Soc., 1994, 116, 6989-6990.
79. Tait, B. D.; Hagen, S.; Domagala, J.; Ellsworth, E. L.; Gajda, C.; Hamilton, H. W.; Prasad, J. V.; Ferguson, D.; Graham, N.; Hupe, D.; Nouhan, C.; Tummino, P. J.; Humblet, C.; Lunney, E. A.; Pavlovsky, A.; Rubin, J.; Gracheck, S. J.; Baldwin, E. T.; Bhat, T. N.; Erickson, J. W.; Gulnik, S. V.; Liu, B. 4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease. J. Med. Chem., 1997, 40, 3781-3792.
80. Hagen, S. E.; Prasad, J. V.; Boyer, F. E.; Domagala, J. M.; Ellsworth, E. L.; Gajda, C.; Hamilton, H. W.; Markoski, L. J.; Steinbaugh, B. A.; Tait, B. D.; Lunney, E. A.; Tummino, P. J.; Ferguson, D.; Hupe, D.; Nouhan, C.; Gracheck, S. J.; Saunders, J. M.; VanderRoest, S. Synthesis of 5,6-dihydro-4-hydroxy-2- pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity. J. Med. Chem., 1997, 40, 3707-3711.
81. Vara Prasad, J. V.; Boyer, F. E.; Domagala, J. M.; Ellsworth, E. L.; Gajda, C.; Hamilton, H. W.; Hagen, S. E.; Markoski, L. J.; Steinbaugh, B. A.; Tait, B. D.; Humblet, C.; Lunney, E. A.; Palovsky, A.; Rubin, J. R.; Ferguson, D.; Graham, N.; Holler, T.; Hupe, D.; Nouhan, C.; Tummino, P. J.; Urumov, A.; Zeikus, E.; Zeikus, G.; Gracheck, S. J.; Saunders, J. M.; VanderRoest, S.; Brodfuehrer, J.; Iyer, K.; Sinz, M.; Gulnik, S. V.; Erickson, J. W.; Non peptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD178390: a lead HIV protease inhibitor. Bioorg. Med. Chem., 1999, 7, 2775-2800
82. Boyer, F. E.; Vara Prasad, J. V.; Domagala, J. M.; Ellsworth, E. L.; Gajda, C.; Hagen, S. E.; Markoski, L. J.; Tait, B. D.; Lunney, E. A.; Palovsky, A.; Ferguson, D.; Graham, N.; Holler, T.; Hupe, D.; Nouhan, C.; Tummino, P. J.; Urumov, A.; Zeikus, E.; Zeikus, G.; Gracheck, S. J.; Saunders, J. M.; VanderRoest, S.; Brodfuehrer, J.; Iyer, K.; Sinz, M.; Gulnik, S. V.; 5,6-dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease. J. Med. Chem., 2000, 43, 843-858.
83. Hagen, S.E.; Domagala, J.; Gajda, C.; Lovdahl, M.; Tait, B. D.; Wise, E.; Holler, T.; Hupe, D.; Nouhan, C.; Urumov, A.; Zeikus, G.; Zeikus, E.; Lunney, E. A.; Pavlovsky, A.; Gracheck, S. J.; Saunders, J.; VanderRoest, S.; Brodfuehrer, J. 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of the heterocyclic substituents at C-6 on the antiviral potency and pharmacokinetic parameters. J. Med. Chem., 2001, 44, 2319-2332.
84. Sun, C. L.; Pang, R. F.; Zhang, H.; Yang, M. Design, synthesis and biological evaluation of novel 4-hydroxypyrone derivatives as HIV-1 protease inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 3257-3262.
85. He, M.; Yang, N.; Sun, C.; Yao, X.; Yang, M. Modification and biological evaluation of novel 4-hydroxy-pyrone derivatives as non-peptidic HIV-1 protease inhibitors. Med. Chem. Res., 2011, 20, 200-209.
86. Lee, Y. S.; Lee, Y. S.; Lee, J. Y.; Kim, S. N.; Lee, C. K.; Park, H. 6-hydroxy-1,3-dioxin-4-ones as non peptidic HIV protease inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 2625-2627.
87. Ding, Y.; Vara Prasad, C. V. N. S.; Smith, K. L.; Chang, E.; Hong, J.; Yao, N. Synthesis of tipranavir analogs as non-peptidic HIV protease inhibitors. Lett. Org. Chem., 2009, 6, 130-133
88. Yehia, N.A.M.; Antuch, W.; Beck, B.; Hess, S.; Schauer- Vukašinović, V.; Almstetter, M.; Furer, P.; Herdtweck, E.; Dömling, A. Novel nonpeptidic inhibitors of HIV-1 protease obtained via a new multicomponent chemistry strategy. Bioorg. Med. Chem. Lett., 2004, 14, 3121-3125.
89. Schobert, R.; Stehle, R.; Walter, H. Tipranavir analogous 3-sulfonylanilidotetronic acids: new synthesis and structuredependent anti-HIV activity. Tetrahedron, 2008, 64, 9401-9407.
90. Wu, X.; Öhrngren, P.; Joshi, A. A.; Trejos, A.; Persson, M.; Arvela, R. K.; Wallberg, H.; Vrang, L.; Rosenquist, Å.; Samuelsson, B. B.; Unge, J.; Larhed, M. Synthesis, X-ray analysis and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors. J. Med. Chem., 2012, 55, 2724-2736.
91. Vieira, E.; Binggeli, A.; Breu, V.; Bur, D.; Fischli, W.; Güller, R.; Hirth, G.; Märki, H. P.; Müller, M.; Oefner, C.; Scalone, M.; Stadler, H.; Wilhelm, M.; Wostl, W. Substituted piperidines -highly potent renin inhibitors due to induced fit adaptation of the active site. Bioorg. Med. Chem. Lett., 1999, 9, 1397-1402.
92. Specker, E.; Böttcher, J.; Brass, S.; Heine, A.; Lilie, H.; Schoop, A.; Müller, G.; Griebenow, N.; Klebe, G. Unexpected novel binding mode of pyrrolidine based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease. ChemMedChem, 2006, 1, 106-117.
93. Specker, E.; Böttcher, J.; Lilie, H.; Heine, A.; Schoop, A.; Müller, G.; Griebenow, N.; Klebe, G. An old target revisited: two new privileged skeletons and unexpected binding mode for HIVprotease inhibitors. Angew. Chem. Int. Ed., 2005, 44, 3140-3144.
94. Blum, A.; Böttcher, J.; Heine, A.; Klebe, G.; Diederich, W. E. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold. J. Med. Chem, 2008, 51, 2078-2087.
95. Böttcher, J.; Blum, A.; Heine, A.; Diederich, W. E.; Klebe, G. Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of the HIV-1 protease. J. Mol. Biol., 2008, 383, 347-357.
96. Luksch, T.; Blum, A.; Klee, N.; Diederich, W. E.; Sotriffer, C. A.; Klebe, G. Pyrrolidine derivatives as plasmepsin inihibitors: binding mode analysis assisted by molecular dynamics simulations of a highly flexible protein. ChemMedChem, 2010, 5, 443-454.
97. Whiting, M.; Tripp, J. C.; Lin, Y. C.; Lindstrom, W.; Olson, A. J.; Elder, J. H.; Sharpless, K. B.; Fokin, V. V. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization. J. Med. Chem., 2006, 49, 7697-7710.